Notes
0.5 μL of vitreous fluid were collected and immediately processed (no-wash lysis) by flow cytometry, and 6700 events were analyzed.
Intravitreal rituximab (two doses, 1 mg/0.1 mL each); R-BAM: three courses of rituximab (375 mg/m2, weekly for 4 weeks) and carmustine (100 mg/m2), cytarabine (3 g/m2), and methotrexate (3 g/m2 administered over 4 h) on days 1, 2, and 3, respectively. Autologous stem cell trasplantation was conditioned with carmustine (400 mg/m2 on day −6) and thiotepa (5.09 mg/Kg days −5 and −4).
References
Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, Lightman S (2014) Primary intraocular lymphoma. Surv Ophthalmol 59:503–516. doi:10.1016/j.survophthal.2013.12.001
Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, Siegal T, Doolittle ND, Batchelor T, Herrlinger U, Neuwelt EA, Laperriere N, Chamberlain MC, Blay JY, Ferreri AJ, Omuro AM, Thiel E, Abrey LE (2007) Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18:1851–1855. doi:10.1093/annonc/mdm340
Kimura K, Usui Y, Goto H, Japanese Intraocular Lymphoma Study Group (2012) Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 56:383–389. doi:10.1007/s10384-012-0150-7
Larouche JF, Berger F, Chassagne-Clément C, Ffrench M, Callet-Bauchu E, Sebban C, Ghesquières H, Broussais-Guillaumot F, Salles G, Coiffier B (2010) Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28:2094–2100. doi:10.1200/JCO.2009.24.5860
Zhang J, Chen B, Xu X (2014) Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma 55:509–514. doi:10.3109/10428194.2013.811239
Sancho JM, Ribera JM, en representación del Grupo de Trabajo sobre Diagnóstico, Prevención y Tratamiento de la Infiltración del SNC en pacientes con LBDCG (2016) Central nervous system relapse in diffuse large B cell lymphoma: risk factors. Med Clin (Barc) 146:74–80. doi:10.1016/j.medcli.2009.04.047
Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, Hoyng C, Cordero-Coma M, Tomkins-Netzer O, Rozalski A, Tugal-Tutkun I, Guex-Crosier Y, Los LI, Bollemeijer JG, Nolan A, Pawade J, Willermain F, Bodaghi B, ten Dam-van Loon N, Dick A, Zierhut M, Lightman S, Mackensen F, Moulin A, Erckens R, Wensing B, le Hoang P, Lokhorst H, Rothova A (2015) Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol 133:191–197. doi:10.1001/jamaophthalmol.2014.4755
Davis JL (2013) Intraocular lymphoma: a clinical perspective. Eye (Lond) 27:153–162. doi:10.1038/eye.2012.250
Zaldivar RA, Martin DF, Holden JT, Grossniklaus HE (2004) Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology 111:1762–1767. doi:10.1016/j.ophtha.2004.03.021
Davis JL, Miller DM, Ruiz P (2005) Diagnostic testing of vitrectomy specimens. Am J Ophthalmol 140:822–829. doi:10.1016/j.ajo.2005.05.032
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Informed consent
The patient gave informed consent for part of her medical history to be published.
Rights and permissions
About this article
Cite this article
Sarrate, E., Sorigue, M., Carbajal, M. et al. Late isolated intraocular relapse of a systemic diffuse large B-cell lymphoma detected by flow cytometry. Ann Hematol 96, 523–524 (2017). https://doi.org/10.1007/s00277-016-2895-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2895-4